Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
December 16, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2024
General
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
December 9, 2024
General
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
November 26, 2024
General
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
November 21, 2024
General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 15, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 6, 2024
Earnings
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
November 5, 2024
General
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
October 17, 2024
General
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
October 16, 2024
General
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
October 8, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 23, 2024
General
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
August 28, 2024
General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 14, 2024
General
Ryan Reynolds Announces More to Parkinson’s® Campaign
August 7, 2024
General
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 6, 2024
Earnings
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
July 24, 2024
General
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
July 18, 2024
General
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
June 18, 2024
General
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
May 17, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
General
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 9, 2024
General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 8, 2024
Earnings
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
April 29, 2024
General
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
April 24, 2024
General
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
April 22, 2024
General
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
April 19, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 17, 2024
General
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 2, 2024
General
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
April 1, 2024
General
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 15, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024
General
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
March 11, 2024
Earnings
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
February 29, 2024
General
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
February 27, 2024
Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
February 21, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2024
General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
January 31, 2024
General
Acadia Announces Additions to Executive Team
January 19, 2024
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2024
General
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
December 21, 2023
General
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
December 18, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2023
General
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
December 13, 2023
General
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
November 30, 2023
General
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
November 27, 2023
General
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
November 21, 2023
General
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
November 14, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 2, 2023
Earnings
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
October 31, 2023
General
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
October 23, 2023
General
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
October 19, 2023
General
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
October 18, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2023
General
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
September 18, 2023
Company Statement
Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin)
August 30, 2023
General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 14, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 2, 2023
Earnings
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
August 1, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2023
General
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
July 19, 2023
General
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
July 13, 2023
General
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
June 26, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2023
General
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
June 8, 2023
General
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
June 1, 2023
General
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 8, 2023
Earnings
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
May 5, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2023
General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
April 25, 2023
General
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
April 20, 2023
General
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 17, 2023
General
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
April 11, 2023
General
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
March 11, 2023
General
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
February 27, 2023
Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
February 14, 2023
General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
February 13, 2023
General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 9, 2023
General
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
January 3, 2023
General
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
December 21, 2022
General
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
November 8, 2022
General
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 2, 2022
Earnings
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
October 27, 2022
General
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
October 20, 2022
General
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
October 13, 2022
General
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
October 4, 2022
General
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
September 12, 2022
General
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
September 1, 2022
General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
August 8, 2022
Earnings
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 5, 2022
General
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
July 25, 2022
General
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
July 18, 2022
General
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
June 18, 2022
General
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
June 17, 2022
General
Acadia Pharmaceuticals Stock Trading Halted Today
May 4, 2022
Earnings
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
May 3, 2022
General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 2, 2022
General
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
April 21, 2022
General
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
April 18, 2022
Earnings
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
March 22, 2022
General
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
March 10, 2022
General
Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022
March 9, 2022
General
Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
March 3, 2022
General
Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
February 28, 2022
Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
February 16, 2022
General
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
February 14, 2022
General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
February 11, 2022
General
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
January 10, 2022
General
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
December 22, 2021
General
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
December 20, 2021
General
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
December 14, 2021
General
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
December 6, 2021
Earnings
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
December 1, 2021
General
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
November 16, 2021
General
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
November 8, 2021
Earnings
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 2, 2021
General
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
November 1, 2021
General
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
October 27, 2021
General
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
October 25, 2021
General
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
September 2, 2021
General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
August 4, 2021
Earnings
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
July 21, 2021
General
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
July 21, 2021
General
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
July 14, 2021
General
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
June 3, 2021
General
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
May 26, 2021
General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 5, 2021
Earnings
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
May 4, 2021
General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
April 21, 2021
General
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
April 5, 2021
General
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
March 8, 2021
General
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
February 24, 2021
Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
February 19, 2021
General
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
February 18, 2021
General
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
February 10, 2021
General
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
November 10, 2020
General
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
November 4, 2020
Earnings
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
October 26, 2020
General
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
October 21, 2020
General
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
October 14, 2020
General
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
October 6, 2020
General
Michael J. Fox Foundation and Acadia Pharmaceuticals Partner to Share Resources and Foster Dialogue on Cognitive Changes and Other Non-Motor Symptoms in Parkinson’s Disease
October 1, 2020
General
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
September 2, 2020
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
August 31, 2020
General
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
August 25, 2020
General
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
August 12, 2020
General
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
August 5, 2020
Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
July 29, 2020
General
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
July 22, 2020
General
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
July 20, 2020
General
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
July 20, 2020
Earnings
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
June 15, 2020
General
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
June 2, 2020
General
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
May 28, 2020
General
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
May 26, 2020
General
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
May 21, 2020
General
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
May 7, 2020
Earnings
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
May 7, 2020
General
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
May 5, 2020
General
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
April 15, 2020
General
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
March 3, 2020
General
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
February 26, 2020
Earnings
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020
General
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
February 12, 2020
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
January 7, 2020
General
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
December 18, 2019
General
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
December 5, 2019
General
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
November 25, 2019
Earnings
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
November 11, 2019
General
ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
November 4, 2019
General
ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
October 30, 2019
General
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
October 30, 2019
Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
October 16, 2019
General
ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019
October 7, 2019
General
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
October 3, 2019
General
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting
September 25, 2019
General
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
September 24, 2019
Earnings
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
September 23, 2019
General
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
September 20, 2019
General
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 19, 2019
General
ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
September 18, 2019
General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
September 17, 2019
General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 9, 2019
General
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
September 4, 2019
General
ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019
July 31, 2019
Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
July 22, 2019
Earnings
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
July 17, 2019
General
ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
June 25, 2019
General
New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
June 4, 2019
General
ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
May 18, 2019
General
ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
May 7, 2019
General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
May 1, 2019
Earnings
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
April 25, 2019
General
ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
April 17, 2019
General
ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
April 11, 2019
General
ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
April 2, 2019
General
ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
April 1, 2019
General
ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
March 27, 2019
General
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
March 4, 2019
General
ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
February 26, 2019
Earnings
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
February 21, 2019
General
ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
February 12, 2019
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
December 20, 2018
General
ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
November 30, 2018
General
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 28, 2018
General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
November 26, 2018
General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
November 6, 2018
Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
October 31, 2018
Earnings
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
September 26, 2018
General
ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
September 25, 2018
General
ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
September 20, 2018
General
FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
September 10, 2018
General
Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
September 4, 2018
General
ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
August 8, 2018
Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
August 6, 2018
General
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
July 30, 2018
General
ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
July 19, 2018
General
ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
June 29, 2018
General
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
June 13, 2018
General
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
June 6, 2018
General
ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
May 8, 2018
General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
May 4, 2018
Earnings
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
May 2, 2018
General
ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
May 1, 2018
General
ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
April 27, 2018
General
ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
April 27, 2018
General
ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
April 23, 2018
General
PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
March 20, 2018
General
ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
March 6, 2018
General
ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
February 27, 2018
Earnings
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
February 20, 2018
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
January 2, 2018
General
ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
December 13, 2017
General
ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development
November 21, 2017
General
ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
November 7, 2017
Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results
November 3, 2017
General
ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting
October 31, 2017
General
ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
October 4, 2017
General
ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis
September 19, 2017
General
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
August 8, 2017
Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results
August 1, 2017
General
ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017
July 25, 2017
General
ACADIA Pharmaceuticals Named to Forbes Magazine’s List of World’s Most Innovative Growth Companies
May 9, 2017
Earnings
ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results
May 8, 2017
General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017
May 2, 2017
General
ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017
March 30, 2017
General
ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
March 29, 2017
General
ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017
February 28, 2017
Earnings
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
February 27, 2017
General
ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017
February 21, 2017
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
January 3, 2017
General
ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017
December 20, 2016
Earnings
ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis
December 1, 2016
General
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder
November 15, 2016
General
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia
November 7, 2016
Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results
November 3, 2016
General
ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia
November 1, 2016
General
ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016
October 31, 2016
General
ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation
October 11, 2016
General
ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™
September 20, 2016
General
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
September 19, 2016
General
ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit
September 6, 2016
General
ACADIA Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2016
August 24, 2016
General
ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
August 23, 2016
General
ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 10, 2016
General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
August 8, 2016
General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
August 4, 2016
Earnings
ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
July 29, 2016
General
ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
June 27, 2016
General
ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index
June 16, 2016
General
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
June 1, 2016
General
ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
May 31, 2016
General
ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
May 5, 2016
Earnings
ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
May 4, 2016
General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
May 2, 2016
General
ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016
April 29, 2016
General
FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
April 6, 2016
General
ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
March 29, 2016
General
FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
March 29, 2016
General
ACADIA Pharmaceuticals Stock Trading Halted Today
March 1, 2016
General
ACADIA Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016
February 29, 2016
Earnings
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
February 23, 2016
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
February 3, 2016
General
ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016
January 29, 2016
General
ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
January 25, 2016
General
ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
January 11, 2016
General
ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
January 7, 2016
General
ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016
January 7, 2016
General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
January 5, 2016
General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 15, 2015
General
ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors
November 30, 2015
General
ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development
November 30, 2015
General
ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors
November 5, 2015
Earnings
ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
November 4, 2015
General
ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015
November 2, 2015
General
ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis
October 29, 2015
General
ACADIA Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2015
September 22, 2015
General
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
September 3, 2015
General
ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
September 3, 2015
General
ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
August 6, 2015
General
ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
August 6, 2015
General
ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association
August 5, 2015
General
ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development
July 30, 2015
General
ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
June 17, 2015
General
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
June 16, 2015
General
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
May 26, 2015
General
ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015
May 7, 2015
General
ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results
May 6, 2015
General
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015
April 30, 2015
General
ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015
April 7, 2015
General
ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015
March 26, 2015
General
ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors
ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZID™ NDA Submission
February 26, 2015
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014
February 24, 2015
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
February 19, 2015
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
January 6, 2015
General
ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
December 8, 2014
General
ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders
November 25, 2014
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
November 13, 2014
General
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
November 10, 2014
General
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission
November 3, 2014
General
ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014
September 2, 2014
General
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis
August 28, 2014
General
ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin
August 5, 2014
General
ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results
July 29, 2014
General
ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014
July 15, 2014
General
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
June 17, 2014
General
ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
May 27, 2014
General
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
May 6, 2014
General
ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
May 1, 2014
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
April 29, 2014
General
ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
April 1, 2014
General
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
March 5, 2014
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
March 5, 2014
General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
March 3, 2014
General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 27, 2014
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
February 20, 2014
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
November 26, 2013
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
November 14, 2013
General
ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis
November 6, 2013
General
ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results
November 1, 2013
General
ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin
October 30, 2013
General
ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013
September 3, 2013
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
August 19, 2013
General
ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
August 6, 2013
General
ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results
July 30, 2013
General
ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013
July 2, 2013
General
ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013
July 1, 2013
General
ACADIA Pharmaceuticals Added to Russell 2000 Index
June 18, 2013
General
ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders
June 3, 2013
General
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development
May 29, 2013
General
ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013
May 20, 2013
General
ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
May 20, 2013
General
ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
May 15, 2013
General
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
May 14, 2013
General
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 7, 2013
General
ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
April 30, 2013
General
ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
April 25, 2013
General
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
April 11, 2013
General
ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
March 21, 2013
General
ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
March 13, 2013
General
ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013
March 12, 2013
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
March 5, 2013
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013
February 25, 2013
General
ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
February 5, 2013
General
ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013
January 22, 2013
General
ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors
December 20, 2012
General
ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program
December 12, 2012
General
ACADIA Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference Today, December 12, 2012
December 12, 2012
General
ACADIA Pharmaceuticals Announces $86 Million Equity Financing
November 27, 2012
General
ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
November 26, 2012
General
ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III Pimavanserin Parkinson’s Disease Psychosis Trial
November 5, 2012
General
ACADIA Pharmaceuticals Reports Third Quarter 2012 Financial Results
October 29, 2012
General
ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 5, 2012
September 5, 2012
General
ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis
August 29, 2012
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
August 8, 2012
General
ACADIA Pharmaceuticals Reports Second Quarter 2012 Financial Results
August 1, 2012
General
ACADIA Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 8, 2012
July 9, 2012
General
ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer’s Disease Psychosis
July 9, 2012
General
ACADIA Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference on July 13, 2012
May 15, 2012
General
ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012
May 8, 2012
General
ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results
May 1, 2012
General
ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012
April 13, 2012
General
ACADIA Pharmaceuticals to Present at the 19th
Annual Future Leaders in the Biotech Industry Conference on April 20,
2012
March 28, 2012
General
ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012
March 27, 2012
General
ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease
March 6, 2012
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011
March 5, 2012
General
ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
February 29, 2012
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
February 28, 2012
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012
February 6, 2012
General
ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
January 30, 2012
General
ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors
December 7, 2011
General
ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011
November 9, 2011
General
ACADIA Pharmaceuticals Reports Third Quarter 2011 Financial Results
November 7, 2011
General
ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma
November 2, 2011
General
ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011
September 21, 2011
General
ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities
Healthcare Conference on September 28, 2011
September 6, 2011
General
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
August 10, 2011
General
ACADIA Pharmaceuticals Reports Second Quarter 2011 Financial Results
August 3, 2011
General
ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011
May 17, 2011
General
ACADIA Pharmaceuticals Awarded Grant from National Institutes of Health for the Development of Novel ER-beta Agonists
May 10, 2011
General
ACADIA Pharmaceuticals Reports First Quarter 2011 Financial Results
May 4, 2011
General
ACADIA Pharmaceuticals to Present at the Tenth Annual JMP Securities Research Conference on May 11, 2011
May 3, 2011
General
ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011
April 1, 2011
General
ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
March 29, 2011
General
ACADIA Pharmaceuticals to Present at the Tenth Annual Needham Healthcare Conference on April 5, 2011
March 10, 2011
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
March 3, 2011
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011
February 8, 2011
General
ACADIA Pharmaceuticals to Present at the Thirteenth Annual BIO CEO & Investor Conference on February 15, 2011
January 10, 2011
General
ACADIA Pharmaceuticals Announces $15 Million Private Placement
November 9, 2010
General
ACADIA Pharmaceuticals Reports Third Quarter 2010 Financial Results
November 9, 2010
General
ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel Nurr1-RXR Agonists to Treat Parkinson's Disease
November 2, 2010
General
ACADIA Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 9, 2010
October 28, 2010
General
ACADIA Pharmaceuticals Enters Agreement with Biovail to Conclude Collaboration and Regain North American Rights to Pimavanserin
September 22, 2010
General
ACADIA Pharmaceuticals to Present at the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010
September 7, 2010
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
August 9, 2010
General
ACADIA Pharmaceuticals Reports Second Quarter 2010 Financial Results
August 2, 2010
General
ACADIA Pharmaceuticals to Announce Second Quarter 2010 Financial
Results on August 9, 2010
July 29, 2010
General
ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial
with Pimavanserin for Parkinson's Disease Psychosis
June 2, 2010
General
ACADIA Pharmaceuticals To Present at the Ninth Annual Needham
Healthcare Conference on June 9, 2010
May 10, 2010
General
ACADIA Pharmaceuticals Reports First Quarter 2010 Financial Results
May 5, 2010
General
ACADIA Pharmaceuticals to Present at the Ninth Annual JMP Securities
Research Conference on May 12, 2010
May 3, 2010
General
ACADIA Pharmaceuticals to Announce First Quarter 2010 Financial
Results on May 10, 2010
April 14, 2010
General
Dr. Joseph Friedman to Present Data From ACADIA Pharmaceuticals' First Phase III Trial With Pimavanserin for Parkinson's Disease Psychosis at the 62nd American Academy of Neurology Annual Meeting
March 9, 2010
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth
Quarter and Year Ended December 31, 2009
March 2, 2010
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2009
Financial Results on March 9, 2010
February 1, 2010
General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor
Conference on February 8, 2010
November 9, 2009
General
ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results
November 2, 2009
General
ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009
October 20, 2009
General
ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009
October 6, 2009
General
ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2009
October 6, 2009
General
ACADIA Pharmaceuticals Provides Update on Pimavanserin Collaborative Development Program
September 1, 2009
General
ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
August 5, 2009
General
ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results
July 29, 2009
General
ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009
June 3, 2009
General
ACADIA Pharmaceuticals to Present at the Eighth Annual Needham Life Sciences Conference on June 10, 2009
May 13, 2009
General
ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009
May 11, 2009
General
ACADIA Pharmaceuticals Reports First Quarter 2009 Financial Results
May 6, 2009
General
ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
May 5, 2009
General
ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009
May 4, 2009
General
ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America
March 25, 2009
General
ACADIA Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs
March 9, 2009
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2008
March 4, 2009
General
ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009
March 2, 2009
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
February 3, 2009
General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009
January 7, 2009
General
ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel ER-beta Agonists for the Treatment of Parkinson’s Disease
November 25, 2008
General
ACADIA Pharmaceuticals to Present at The 20th Annual Piper Jaffray Health Care Conference on December 3, 2008
November 5, 2008
General
ACADIA Pharmaceuticals Reports Third Quarter 2008 Financial Results
November 3, 2008
General
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
October 29, 2008
General
ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008
October 21, 2008
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
September 29, 2008
General
ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008
September 5, 2008
General
ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility
August 28, 2008
General
ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008
ACADIA Pharmaceuticals Announces Second Quarter 2008 Financial Results and Strategic Restructuring
July 29, 2008
General
ACADIA Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
June 16, 2008
General
ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial
June 4, 2008
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
May 14, 2008
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
May 5, 2008
General
ACADIA Pharmaceuticals Reports First Quarter 2008 Financial Results
May 5, 2008
General
ACADIA Pharmaceuticals Announces Election of Laura A. Brege to Board of Directors
April 30, 2008
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
April 28, 2008
General
ACADIA Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 5, 2008
April 16, 2008
General
ACADIA Pharmaceuticals to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting
April 4, 2008
General
ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104, ACP-105 and Its Muscarinic Discovery Program at Experimental Biology 2008 Meeting
March 31, 2008
General
ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
March 28, 2008
General
ACADIA Pharmaceuticals to Present at the 8th Annual Fortis Bank Biotechnology Conference
March 11, 2008
General
ACADIA Pharmaceuticals to Present at Lehman Brothers 11th Annual Global Healthcare Conference
March 5, 2008
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
February 27, 2008
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 5, 2008
February 12, 2008
General
ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development
February 5, 2008
General
ACADIA Pharmaceuticals Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
February 4, 2008
General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2008
December 26, 2007
General
ACADIA Pharmaceuticals to Present at the 26th Annual JP Morgan Healthcare Conference on January 7, 2008
December 14, 2007
General
ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule
December 6, 2007
General
ACADIA Pharmaceuticals to Webcast Its Analyst and Investor Meeting on December 14, 2007
November 7, 2007
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
November 5, 2007
General
ACADIA Pharmaceuticals Reports Third Quarter 2007 Financial Results
November 2, 2007
General
ACADIA Pharmaceuticals to Present Preclinical Data on Its Advanced Schizophrenia Programs at the 37th Annual Meeting of the Society for Neuroscience
October 29, 2007
General
ACADIA Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 5, 2007
October 26, 2007
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
October 3, 2007
General
ACADIA Pharmaceuticals to Present at BIO InvestorForum 2007 on October 10, 2007
September 25, 2007
General
ACADIA Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
September 19, 2007
General
ACADIA Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
August 6, 2007
General
ACADIA Pharmaceuticals Reports Second Quarter 2007 Financial Results
August 1, 2007
General
ACADIA Pharmaceuticals to Present at the Canaccord Adams 27th Annual Global Growth Conference
July 30, 2007
General
ACADIA Pharmaceuticals to Announce Second Quarter 2007 Financial Results on August 6, 2007
July 16, 2007
General
ACADIA Pharmaceuticals Earns Milestone on Advancement of Glaucoma Drug Candidate
June 26, 2007
General
ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia
June 11, 2007
General
ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
May 24, 2007
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
May 8, 2007
General
ACADIA Pharmaceuticals Reports First Quarter 2007 Financial Results
May 1, 2007
General
ACADIA Pharmaceuticals to Announce First Quarter 2007 Financial Results on May 8, 2007
April 24, 2007
General
Pimavanserin Approved by USAN as Nonproprietary Name for ACADIA Drug Candidate ACP-103
April 20, 2007
General
ACADIA Pharmaceuticals Announces Exercise of Over-Allotment by Underwriters
April 18, 2007
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
April 4, 2007
General
ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering
April 2, 2007
General
ACADIA Pharmaceuticals Announces Proposed Public Stock Offering
March 29, 2007
General
ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
March 19, 2007
General
ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
March 14, 2007
General
ACADIA Pharmaceuticals to Present at Lehman Brothers 10th Annual Global Healthcare Conference
March 6, 2007
General
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2006
February 27, 2007
General
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2006 Financial Results on March 6, 2007
February 6, 2007
General
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 13, 2007
January 3, 2007
General
ACADIA Pharmaceuticals to Present at the 25th Annual JP Morgan Healthcare Conference on January 11, 2007
December 4, 2006
General
ACADIA Pharmaceuticals Adds Complementary Intellectual Property for Serotonin Platform
November 6, 2006
General
ACADIA Pharmaceuticals Reports Third Quarter 2006 Financial Results
November 1, 2006
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
October 30, 2006
General
ACADIA Pharmaceuticals to Announce Third Quarter 2006 Financial Results on November 6, 2006
October 23, 2006
General
ACADIA Pharmaceuticals to Support Launch of New Company Focused on Substance Abuse Therapeutics
October 11, 2006
General
ACADIA Pharmaceuticals to Present at BIO InvestorForum 2006 on October 18, 2006
September 25, 2006
General
ACADIA Pharmaceuticals Announces Accelerated Timing of ACP-103 Phase II Trial in Patients with Schizophrenia; Top-Line Results for Complete 400-Patient Study Expected in Q1 2007
September 12, 2006
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
August 8, 2006
General
ACADIA Pharmaceuticals Reports Second Quarter 2006 Financial Results
August 3, 2006
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
August 2, 2006
General
ACADIA Pharmaceuticals to Announce Second Quarter 2006 Financial Results on August 8, 2006; ACADIA to Host Conference Call and Webcast on Tuesday, August 8, 2006, at 5:00 p.m. Eastern Time
July 13, 2006
General
ACADIA Pharmaceuticals Announces Encouraging Results from Initial Clinical Trials with ACP-104 in Patients with Schizophrenia
June 20, 2006
General
ACADIA Pharmaceuticals to Present at the Jefferies Life Sciences Conference on June 27, 2006
June 8, 2006
General
ACADIA Pharmaceuticals to Present at Needham's Fifth Annual Biotechnology and Medical Technology Conference
June 5, 2006
General
ACADIA Pharmaceuticals Announces Appointment of Roger G. Mills, M.D., as Executive Vice President, Development
May 15, 2006
General
ACADIA Pharmaceuticals Added to NASDAQ Biotech Index
May 10, 2006
General
ACADIA Pharmaceuticals Reports First Quarter 2006 Financial Results
May 8, 2006
General
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
May 3, 2006
General
ACADIA Pharmaceuticals to Announce First Quarter 2006 Financial Results on May 10, 2006
April 28, 2006
General
ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering
April 24, 2006
General
ACADIA Pharmaceuticals Announces Proposed Public Stock Offering
ACADIA Pharmaceuticals Reports Results From Phase II Study of ACP-103 in Schizophrenia Patients With Haloperidol-Induced Akathisia
November 10, 2005
General
ACADIA Pharmaceuticals Announces Initial Results From Ongoing Single-Dose Clinical Trial of ACP-104 in Schizophrenia Patients
November 10, 2005
General
Acadia Pharmaceuticals Reports Third Quarter 2005 Financial Results
November 3, 2005
General
ACADIA Pharmaceuticals to Announce Third Quarter 2005 Financial Results on November 10, 2005
November 1, 2005
General
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 8, 2005
October 13, 2005
General
ACADIA Pharmaceuticals to Present at BIO InvestorForum 2005 on October 20, 2005
October 3, 2005
General
ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Clinical Program
September 22, 2005
General
ACADIA Pharmaceuticals Study Identifies Molecular Properties of ACP-104 That Predict Unique Antipsychotic Activity
September 20, 2005
General
ACADIA Pharmaceuticals to Present at the 2005 UBS Global Life Sciences Conference on September 27, 2005
September 16, 2005
General
ACADIA Pharmaceuticals Officially Opens New Chemistry R&D Facility in Sweden
September 13, 2005
General
ACADIA Pharmaceuticals Announces Election of Michael T. Borer to Board of Directors
August 24, 2005
General
ACADIA Pharmaceuticals Comments on Civil Litigation
August 17, 2005
General
ACADIA Pharmaceuticals to Present at the 8th Annual San Diego Growth Conference on August 19, 2005
August 10, 2005
General
ACADIA Pharmaceuticals Reports Second Quarter 2005 Financial Results
August 3, 2005
General
ACADIA Pharmaceuticals to Announce Second Quarter 2005 Financial Results on August 10, 2005
July 27, 2005
General
ACADIA Pharmaceuticals to Present at the 25th Annual Adams Harkness Summer Seminar on August 3, 2005
June 22, 2005
General
ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease
May 19, 2005
General
ACADIA Pharmaceuticals to Present at the Fourth Annual Needham Biotechnology Conference
